# Nurix Therapeutics, Inc.: overview

NRIX · Nasdaq · CIK 1549595 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Nov 30

Pages: [Overview](/companies/nrix.md) · [Financials](/companies/nrix/financials.md) · [Filings](/companies/nrix/filings.md) · [Insiders](/companies/nrix/insiders.md)

Latest reported revenue: [$673.1m](/filings/0001549595-26-000049.md) for Q3 FY2026, three months to 2026-08-31, from the 10-Q filed Oct 13, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001549595-26-000049).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-11-30) | Q1 FY2025 (2025-02-28) | Q2 FY2025 (2025-05-31) | Q3 FY2025 (2025-08-31) | Q4 FY2025 (2025-11-30) | Q1 FY2026 (2026-02-28) | Q2 FY2026 (2026-05-31) | Q3 FY2026 (2026-08-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [13.3 d](/filings/0001549595-26-000016.md) | [18.5](/filings/0001549595-26-000025.md) | [44.1](/filings/0001549595-26-000040.md) | [7.9](/filings/0001549595-26-000049.md) | [13.6 d](/filings/0001549595-26-000016.md) | [6.3](/filings/0001549595-26-000025.md) | [9.0](/filings/0001549595-26-000040.md) | [673](/filings/0001549595-26-000049.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(486.7%) d](/filings/0001549595-26-000016.md) | [(340.7%)](/filings/0001549595-26-000025.md) | [(109.7%)](/filings/0001549595-26-000040.md) | [(1157.7%)](/filings/0001549595-26-000049.md) | [(612.0%) d](/filings/0001549595-26-000016.md) | [(1479.4%)](/filings/0001549595-26-000025.md) | [(1041.7%)](/filings/0001549595-26-000040.md) | [83.1%](/filings/0001549595-26-000049.md) |
| Net margin | % | [(440.7%) d](/filings/0001549595-26-000016.md) | [(305.4%)](/filings/0001549595-26-000049.md) | [(98.7%)](/filings/0001549595-26-000049.md) | [(1094.8%)](/filings/0001549595-26-000049.md) | [(576.1%) d](/filings/0001549595-26-000016.md) | [(1394.3%)](/filings/0001549595-26-000049.md) | [(990.1%)](/filings/0001549595-26-000049.md) | [81.7%](/filings/0001549595-26-000049.md) |
| Diluted EPS | $ per share | not reported | [(0.67)](/filings/0001549595-26-000025.md) | [(0.52)](/filings/0001549595-26-000040.md) | [(1.03)](/filings/0001549595-26-000049.md) | not reported | [(0.79)](/filings/0001549595-26-000025.md) | [(0.81)](/filings/0001549595-26-000040.md) | [4.73](/filings/0001549595-26-000049.md) |
| Free cash flow | $m | [(50.9) d](/filings/0001549595-26-000016.md) | [(64.6)](/filings/0001549595-26-000025.md) | [(65.8) d](/filings/0001549595-26-000040.md) | [(60.1) d](/filings/0001549595-26-000049.md) | [(73.0) d](/filings/0001549595-26-000016.md) | [(73.0)](/filings/0001549595-26-000025.md) | [(98.5) d](/filings/0001549595-26-000040.md) | [614 d](/filings/0001549595-26-000049.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-11-30) | FY2022 (2022-11-30) | FY2023 (2023-11-30) | FY2024 (2024-11-30) | FY2025 (2025-11-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [29.8](/filings/0001549595-23-000021.md) | [38.6](/filings/0001549595-25-000016.md) | [77.0](/filings/0001549595-26-000016.md) | [54.5](/filings/0001549595-26-000016.md) | [84.0](/filings/0001549595-26-000016.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(396.3%)](/filings/0001549595-23-000021.md) | [(476.0%)](/filings/0001549595-25-000016.md) | [(201.4%)](/filings/0001549595-26-000016.md) | [(390.5%)](/filings/0001549595-26-000016.md) | [(340.2%)](/filings/0001549595-26-000016.md) |
| Net margin | % | [(393.9%)](/filings/0001549595-23-000021.md) | [(466.9%)](/filings/0001549595-25-000016.md) | [(187.0%)](/filings/0001549595-26-000016.md) | [(354.9%)](/filings/0001549595-26-000016.md) | [(314.9%)](/filings/0001549595-26-000016.md) |
| Diluted EPS | $ per share | [(2.73)](/filings/0001549595-23-000021.md) | [(3.71)](/filings/0001549595-25-000016.md) | [(2.65)](/filings/0001549595-26-000016.md) | [(2.88)](/filings/0001549595-26-000016.md) | [(3.05)](/filings/0001549595-26-000016.md) |
| Free cash flow | $m | [(90.0)](/filings/0001549595-23-000021.md) | [(172)](/filings/0001549595-25-000016.md) | [(89.8)](/filings/0001549595-26-000016.md) | [(182)](/filings/0001549595-26-000016.md) | [(263)](/filings/0001549595-26-000016.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/nrix/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $212.8m | 8,770,349 |  | Reduced −155,293 |
| [Vestal Point Capital, LP](/funds/1974915.md) | 2026-06-30 | $195.3m | 8,050,000 |  | Added +1,550,000 |
| [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $187.7m | 7,736,455 |  | Added +1,391,211 |
| [Rubric Capital Management LP](/funds/1687509.md) | 2026-06-30 | $175.3m | 7,227,778 |  | Added +4,753,893 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $133.1m | 5,485,215 |  | Reduced −56,056 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $115.5m | 4,762,484 |  | Reduced −169,515 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $113.5m | 4,677,244 |  | Reduced −463,951 |
| [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $113.0m | 4,658,556 |  | Unchanged |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $109.1m | 4,495,529 |  | Added +68,417 |
| [PERCEPTIVE ADVISORS LLC](/funds/1224962.md) | 2026-06-30 | $104.8m | 4,320,422 |  | Added +609,545 |

## Recent filings

[All 547 filings](/companies/nrix/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-13 | 10:21 ET | [10-Q](/filings/0001549595-26-000049.md) | Quarterly report, period 2026-08-31 | 0001549595-26-000049 |
| 2026-10-13 | 10:19 ET | [8-K](/filings/0001549595-26-000048.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001549595-26-000048 |
| 2026-07-09 | 20:12 ET | [10-Q](/filings/0001549595-26-000040.md) | Quarterly report, period 2026-05-31 | 0001549595-26-000040 |
| 2026-07-09 | 20:09 ET | [8-K](/filings/0001549595-26-000038.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001549595-26-000038 |
| 2026-06-11 | 11:06 ET | [8-K](/filings/0001549595-26-000034.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001549595-26-000034 |
| 2026-06-08 | 10:11 ET | [8-K](/filings/0001549595-26-000030.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001549595-26-000030 |
| 2026-05-15 | 20:03 ET | [8-K](/filings/0001549595-26-000028.md) | 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001549595-26-000028 |
| 2026-04-08 | 10:03 ET | [10-Q](/filings/0001549595-26-000025.md) | Quarterly report, period 2026-02-28 | 0001549595-26-000025 |
| 2026-04-08 | 10:02 ET | [8-K](/filings/0001549595-26-000024.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001549595-26-000024 |
| 2026-03-27 | 10:03 ET | [DEF 14A](/filings/0001140361-26-011492.md) | Proxy statement, period 2026-05-15 | 0001140361-26-011492 |

## Latest annual report

[Form 10-K for the fiscal year ended Nov 30, 2025](/filings/0001549595-26-000016.md), filed Jan 28, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1549595
- Tickers: NRIX
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.